Get the Stockscreener App
1.47
5.14%
-0.08
Klotho Neurosciences Inc stock is traded at $1.47, with a volume of 1.53M.
It is down -5.14% in the last 24 hours and up +554.63% over the past month.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
See More
Previous Close:
$1.55
Open:
$1.52
24h Volume:
1.53M
Relative Volume:
0.04
Market Cap:
$65.31M
Revenue:
-
Net Income/Loss:
$-4.23M
P/E Ratio:
-6.9734
EPS:
-0.2108
Net Cash Flow:
-
1W Performance:
+1.40%
1M Performance:
+554.63%
6M Performance:
+226.01%
1Y Performance:
+0.00%
1-Day Range:
$1.40
$1.52
1-Week Range:
$1.40
$2.45
52-Week Range:
$0.1135
$3.9099
Klotho Neurosciences Inc Stock (KLTO) Company Profile
Name
Klotho Neurosciences Inc
Sector
Industry
Phone
646-916-5315
Address
1115 BROADWAY, NEW YORK
Compare KLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLTO
Klotho Neurosciences Inc
|
1.4705 | 65.31M | 0 | -4.23M | 0 | -0.2108 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.10 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.63 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.67 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.10 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.31 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Klotho Neurosciences Inc Stock (KLTO) Latest News
Klotho Neurosciences terminates share exchange agreement with SkyBell By Investing.com - Investing.com Nigeria
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS - PR Newswire
KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT - StreetInsider
Klotho Neurosciences Raises $11 Million In Funding - citybiz
Klotho Neurosciences Achieves Debt-Free Status with $11M Raise - TipRanks
Klotho Neurosciences raises $11 million, eliminates all debt - Investing.com
Klotho Neurosciences Secures $11M Through Warrants, Eliminates All Debt in Major Financial Turnaround - Stock Titan
Klotho Neurosciences Completes Series B Stock Sale - TipRanks
Klotho Neurosciences IncOn June 9, Terminates Share Exchange Agreement With Skybell Technologies - marketscreener.com
Weekly Recap: 11 Health Press Releases You Need to See - Yahoo Finance
Top Value Stocks To Follow TodayJune 9th - MarketBeat
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
Medical Stocks To Add to Your Watchlist – June 10th - Defense World
What's Happening With Klotho Neurosciences Stock? - Nasdaq
Klotho Neurosciences adjusts warrant terms - Investing.com Australia
Klotho Neurosciences adjusts warrant terms By Investing.com - Investing.com Nigeria
Klotho Neurosciences Amends Public Warrant Pricing - TipRanks
Promising Pharmaceutical Stocks Worth Watching – June 9th - Defense World
Best Medical Stocks To Follow Now – June 9th - Defense World
Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside - FinancialContent
Why Is Klotho Neurosciences Stock (KLTO) Up 175% Today? - The Globe and Mail
Klotho Neurosciences Announces Warrant Repricing Agreement - TipRanks
Klotho Neurosciences: What’s Behind The Nine-Fold Rise In KLTO Stock? - Forbes
Klotho Neurosciences (KLTO) Stock Explodes Over 83% in a Single Day, Capping an Astronomical Monthly Gain - Daily Chhattisgarh News
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
US Stocks Likely To Open Lower: Equities Face 'High Bar' Amid Tariff-Fueled Volatility In The Second Half Of 2025, Says Analyst - Benzinga
Health Care Sector Sees Mixed Results And Strategic Moves - Finimize
Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon - MSN
KLTO, AMD, MSTR, CRCL, TSLA: 5 Trending Stocks TodayAdvanced Micro Devices (NASDAQ:AMD) - Benzinga
Klotho Neurosciences Sees Massive Jump After Promising Gene Study - Finimize
Sector Update: Health Care - marketscreener.com
Crude Oil Moves Higher; Graham Shares Surge After Q4 Results - Benzinga
America's Largest Homebuilder D.R. Horton Makes History as NYSE Texas Founding Member - Stock Titan
US Stocks Mixed; Motorcar Parts of America Posts Upbeat Earnings - Benzinga
NEXT10 Expands Portfolio with Major Real Estate Acquisition: Torreon Group Deal Signals Growth - Stock Titan
Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan
GoodRx Disrupts Pharmacy Market with New Cost-Plus Pricing Model for Independent Stores - Stock Titan
Clene CEO Rob Etherington Set to Reveal Company Updates at Investor Summit Virtual Conference - Stock Titan
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPANREPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO") - PR Newswire
Graco Sets $0.275 Quarterly Dividend Payout: Key Dates and Details for Shareholders - Stock Titan
Dividend Alert: Templeton Dragon Fund Announces Fixed Rate $0.10 Quarterly Distribution Plan - Stock Titan
Sinclair Secures Full Shareholder Support: Board Re-elected, Key Governance Changes Approved - Stock Titan
Quanterix Announces Exclusive Investor Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Special Opportunities Fund Announces New Preferred Stock Dividend: Key Dates and Payment Details Released - Stock Titan
NASB Financial Rewards Shareholders: $0.25 Quarterly Dividend Coming This June - Stock Titan
Granite Construction Sets Next Dividend Payout: Key Dates and Amount Investors Should Know - Stock Titan
Energy Giant Valero Sets Q2 2025 Earnings Date: Key Operations Update Coming July 24 - Stock Titan
Acadia Pharmaceuticals R&D Day: New Pipeline Developments in Neurological and Rare Diseases Revealed - Stock Titan
Klotho Neurosciences Inc Stock (KLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):